Jan 27, 2020 Oncolytics Biotech® Announces Statistically Significant Data Identifying CEACAM6 as a Prospective Prognostic Biomarker for Pelareorep in the Treatment of Pancreatic Adenocarcinoma
Jan 22, 2020 Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer
Jan 13, 2020 Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma
Jan 9, 2020 Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma
Dec 12, 2019 Oncolytics Biotech(R) Announces Abstract Outlining Potential New Biomarker to be Presented at the 2020 Gastrointestinal Cancers Symposium
Dec 9, 2019 Oncolytics Biotech(R) Announces Positive Multiple Myeloma Data Presented at the 61st Annual Meeting & Exposition of the American Society of Hematology
Dec 3, 2019 Oncolytics Biotech(R) Presents Clinical Data at the Fifth Annual Oncolytic Virotherapy Conference Highlighting Definitive Evidence of Systemic Delivery and Replication of Pelareorep in Tumor Tissue
Nov 12, 2019 Oncolytics Biotech(R) Reports 2019 Third Quarter Financial Results and Operational Highlights
